{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:22:25Z","timestamp":1792815745207,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamainternmed.2019.0462","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:05:10Z","timestamp":1559041510000},"page":"906","source":"Crossref","is-referenced-by-count":281,"title":["Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval"],"prefix":"10.1001","volume":"179","author":[{"given":"Bishal","family":"Gyawali","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Oncology, Department of Public Health Sciences, and Division of Cancer Care and Epidemiology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer Phillips","family":"Hey","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ioi190018r3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/0962280207081864","article-title":"Individual- and trial-level surrogacy in colorectal cancer.","volume":"17","author":"Buyse","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"21","key":"ioi190018r4","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/jnci\/djt269","article-title":"Progression-free survival as a surrogate for overall survival in advanced\/recurrent gastric cancer trials: a meta-analysis.","volume":"105","author":"Paoletti","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"ioi190018r5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10120-013-0274-6","article-title":"Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.","volume":"17","author":"Shitara","year":"2014","journal-title":"Gastric Cancer"},{"issue":"8","key":"ioi190018r6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamainternmed.2013.3037","article-title":"Surrogate outcomes in clinical trials: a cautionary tale.","volume":"173","author":"Svensson","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ioi190018r7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"issue":"2","key":"ioi190018r8","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1056\/NEJMp1107201","article-title":"Reputation and precedent in the bevacizumab decision.","volume":"365","author":"Carpenter","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi190018r9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"ioi190018r13","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond.","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"ioi190018r14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study.","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"ioi190018r15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer.","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi190018r16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"ioi190018r17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi190018r18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"ioi190018r19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"ioi190018r20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ioi190018r21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"10167","key":"ioi190018r24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"ioi190018r25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma.","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi190018r26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10122","key":"ioi190018r27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"28","key":"ioi190018r28","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"ioi190018r30","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab.","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ioi190018r31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration.","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"ioi190018r32","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ioi190018r33","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"ioi190018r34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses.","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"ioi190018r35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejca.2011.10.028","article-title":"Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?","volume":"48","author":"Amir","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"ioi190018r36","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/ijc.v144.7","article-title":"Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials.","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"ioi190018r37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis.","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"7","key":"ioi190018r38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","article-title":"Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies.","volume":"22","author":"Blumenthal","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"ioi190018r39","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/annonc\/mdt358","article-title":"Equipoise abandoned? Randomization and clinical trials.","volume":"24","author":"Kurzrock","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"ioi190018r40","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMp1100548","article-title":"Early accelerated approval for highly targeted cancer drugs.","volume":"364","author":"Chabner","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"ioi190018r41","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy combinations in multiple myeloma\u2014known unknowns.","volume":"379","author":"Gormley","year":"2018","journal-title":"N Engl J Med"},{"issue":"10166","key":"ioi190018r42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"ioi190018r43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41571-018-0066-3","article-title":"Reinforcing the social compromise of accelerated approval.","volume":"15","author":"Gyawali","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ioi190018r1","unstructured":"Code of Federal Regulations. \u00a7601.41. https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=c03234aa22abbed0380923a4cc6ab001&mc=true&node=se21.7.601_141&rgn=div8 December 11, 1992. Accessed September 10, 2018."},{"key":"ioi190018r2","unstructured":"US Food and Drug Administration. Accelerated approval for patients. https:\/\/www.fda.gov\/ForPatients\/Approvals\/Fast\/ucm405447.htm. Accessed August 21, 2018."},{"key":"ioi190018r10","unstructured":"US Food and Drug Administration. Surrogate endpoint resources for drug and biologic development. Accessed at https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm606684.htm."},{"key":"ioi190018r11","unstructured":"US Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. Accessed at https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm613636.htm"},{"key":"ioi190018r12","unstructured":"US Food and Drug Administration. Postmarket requirements and commitments. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/pmc\/index.cfm. Accessed April 26, 2019."},{"key":"ioi190018r22","unstructured":"Pembrolizumab fails to improve survival in head and neck squamous cell carcinoma. Accessed at https:\/\/www.healio.com\/hematology-oncology\/head-neck-cancer\/news\/online\/%7Ba214b6c3-ab16-4c8e-abf3-63dd9403e695%7D\/pembrolizumab-fails-to-improve-survival-in-head-and-neck-squamous-cell-carcinoma."},{"key":"ioi190018r23","unstructured":"ESMO 2017 press release: KEYNOTE-040 evaluates pembrolizumab in head and neck cancer. Accessed at https:\/\/www.esmo.org\/Press-Office\/Press-Releases\/KEYNOTE-040-Evaluates-Pembrolizumab-in-Head-and-Neck-Cancer."},{"key":"ioi190018r29","unstructured":"FDA grants bevacizumab full approval in recurrent glioblastoma. The ASCO Post website. https:\/\/www.ascopost.com\/News\/58324. Accessed March 5, 2018."},{"key":"ioi190018r44","unstructured":"LoftusP. Eli Lilly to pull cancer drug from market after failed study. The Wall Street Journal. April 25, 2019. https:\/\/www.wsj.com\/articles\/eli-lilly-to-pull-cancer-drug-from-market-after-failed-study-11556196934. Accessed April 26, 2019."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamainternalmedicine\/article-pdf\/179\/7\/906\/17690741\/jamainternal_gyawali_2019_oi_190018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T11:02:15Z","timestamp":1561978935000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2019.0462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.0462","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}